Self-Replicating RNA Rabies Vaccine Constructs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rabies vaccines face challenges such as the need for multiple injections, unreliable efficacy, and high production costs, limiting their availability and effectiveness, especially in developing countries.
Innovation Solution
Development of nucleic acid constructs encoding modified alphavirus genomes or self-replicating RNA (srRNA) that express rabies virus envelope glycoprotein G, along with recombinant cells and pharmaceutical compositions, to elicit an immune response and prevent or treat rabies infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell culture vaccines are used, then safety and immunogenicity are improved, but production cost and time consumption increase
Solution Approach 1:
The patent replaces traditional mechanical cell culture production methods with a nucleic acid-based expression system. Instead of cultivating cells to produce the vaccine antigen, the invention uses in vitro transcription of RNA molecules encoding the rabies virus glycoprotein, which are then directly administered. This substitution eliminates the time-consuming cell culture process while maintaining antigen production capability.
Solution Approach 2:
The patent changes the fundamental parameter of vaccine production from biological cell culture to biochemical RNA synthesis. By using self-replicating RNA or replicon particles that can replicate the antigen-encoding sequence, the system achieves rapid antigen production without the temporal and resource constraints of traditional cell culture methods.
2Reliability
If multiple injections are required, then vaccine efficacy is maintained, but treatment complexity and time increase
Solution Approach 1:
The patent employs self-replicating RNA or replicon particles that can autonomously replicate the antigen-encoding sequence within host cells after a single administration. This self-service mechanism eliminates the need for multiple injections to maintain adequate antigen levels, as the replicated RNA continues to produce antigen endogenously, thereby simplifying the vaccination protocol while maintaining efficacy.
3Ease of manufacture
If nerve tissue vaccines are used, then historical availability is maintained, but safety risks and reliability decrease
Solution Approach 1:
The patent extracts only the essential functional component (the antigen-encoding genetic information) from the traditional nerve tissue vaccine and separates it from the problematic nerve tissue matrix. By using isolated RNA molecules or replicon particles that encode the rabies glycoprotein without containing any nerve tissue components, the invention eliminates the safety risks associated with autoimmune reactions while preserving the immunogenic function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution enables the production of vaccines that can be delivered at any time, offering improved immune response durability and cost-effectiveness, potentially addressing the global shortage of effective rabies vaccines.
Implementation Method 1
nucleic acid constructs encoding modified alphavirus genomes or self-replicating RNA (srRNA) that express rabies virus envelope glycoprotein G
Implementation Method 2
self-replicating RNA (srRNA) that express rabies virus envelope glycoprotein G
Implementation Method 3
recombinant cells and pharmaceutical compositions... to elicit an immune response
Data Source
AI summary
The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating rabies virus infection.